Autologous transplantation performed in first complete remission (based on reference1 ).
| Author (No. Pts.) . | Conditioning . | In vitro Purging . | Stem Cell Source . | Median Follow Up (mo.) . | PFS . | OS . | Early TRM* . | Comments . |
|---|---|---|---|---|---|---|---|---|
| *Early TRM, treatment-related mortality usually defined as occurring within 100 days after autologous stem cell transplantation (ASCT). | ||||||||
| Abbreviations: PFS, progression-free survival; OS, overall survival; MoAB, monoclonal antibody; VP, etoposide; BM, bone marrow; PB, peripheral blood; Cy, cyclophosphamide; TBI, total body irradiation: BEAM, BCNU/etoposide/cytarabine/melphalan; FL, follicular lymphoma; MDS, myelodysplastic syndrome; PCR, polymerase chain reaction; C′, complement | ||||||||
| Freedman (77) | Cy/TBI | Anti B MoABb + C′ | BM | 45mo | 63% @ 3 yr | 89% @ 3 yr | 3% | 5 secondary hematologic malignancies. |
| Horning (37) | Cy/TBI/VP | Anti B MoAB + C′ | BM | 78mo | 60% @ 10 yr | 86% @ 10 yr | 5% | 2 secondary hematologic malignancies. |
| Corradini (40) | Mitoxantrone/ Melphalan | none | PB | 90mo | 57% @ 12 yr | 60% @ 12 yr | 1% | 11 pts had transformed FL. 3 secondary hematologic malignancies. |
| Voso (70) | Cy/TBI | CD34+ selection (10%); None (90%) | PB | 44mo | 78% @ 44 mo | 86% @ @ 44 mo | 5% | |
| Lenz (140) | TBI/Cy | none | PB | 53mo | 65% @ 60 mo | NS | 1% | Randomized trial; 6.6% secondary MDS in transplant group. |
| Colombat (27) | Cy/TBI | CD34+ selection or Anti B MoAB + C′ | PB | 72 mo | 55% @ 72 mo | 64% @ 72 mo | Randomized trial. MDS increased in transplant group. | |
| Seyfarth (33) | Cy/TBI 79% BEAM 21% | none | PB | 48 mo | 76% @ 48 mo | 92% @ 48 mo | ||
| Bociek (43) | not stated | none | PB | 36 mo | 36% @ 60 mo | 63% @ 60 mo | ||
| González- Barca (15) | Cy/TBI | immunomagnetic purging | BM 9 PB 6 | 56 mo | 83% @ 56 mo | NS | 13% | 6/8 BM PCR negative for BCL-2. |
| Linassier (42) | TBI 48% non-TBI 52% | Immunomagnetic purging 36% | BM 88% PB 12% | 43mo | 66% @ 43 mo | 83% @ 43 mo | No prognostic factors identified. | |
| Author (No. Pts.) . | Conditioning . | In vitro Purging . | Stem Cell Source . | Median Follow Up (mo.) . | PFS . | OS . | Early TRM* . | Comments . |
|---|---|---|---|---|---|---|---|---|
| *Early TRM, treatment-related mortality usually defined as occurring within 100 days after autologous stem cell transplantation (ASCT). | ||||||||
| Abbreviations: PFS, progression-free survival; OS, overall survival; MoAB, monoclonal antibody; VP, etoposide; BM, bone marrow; PB, peripheral blood; Cy, cyclophosphamide; TBI, total body irradiation: BEAM, BCNU/etoposide/cytarabine/melphalan; FL, follicular lymphoma; MDS, myelodysplastic syndrome; PCR, polymerase chain reaction; C′, complement | ||||||||
| Freedman (77) | Cy/TBI | Anti B MoABb + C′ | BM | 45mo | 63% @ 3 yr | 89% @ 3 yr | 3% | 5 secondary hematologic malignancies. |
| Horning (37) | Cy/TBI/VP | Anti B MoAB + C′ | BM | 78mo | 60% @ 10 yr | 86% @ 10 yr | 5% | 2 secondary hematologic malignancies. |
| Corradini (40) | Mitoxantrone/ Melphalan | none | PB | 90mo | 57% @ 12 yr | 60% @ 12 yr | 1% | 11 pts had transformed FL. 3 secondary hematologic malignancies. |
| Voso (70) | Cy/TBI | CD34+ selection (10%); None (90%) | PB | 44mo | 78% @ 44 mo | 86% @ @ 44 mo | 5% | |
| Lenz (140) | TBI/Cy | none | PB | 53mo | 65% @ 60 mo | NS | 1% | Randomized trial; 6.6% secondary MDS in transplant group. |
| Colombat (27) | Cy/TBI | CD34+ selection or Anti B MoAB + C′ | PB | 72 mo | 55% @ 72 mo | 64% @ 72 mo | Randomized trial. MDS increased in transplant group. | |
| Seyfarth (33) | Cy/TBI 79% BEAM 21% | none | PB | 48 mo | 76% @ 48 mo | 92% @ 48 mo | ||
| Bociek (43) | not stated | none | PB | 36 mo | 36% @ 60 mo | 63% @ 60 mo | ||
| González- Barca (15) | Cy/TBI | immunomagnetic purging | BM 9 PB 6 | 56 mo | 83% @ 56 mo | NS | 13% | 6/8 BM PCR negative for BCL-2. |
| Linassier (42) | TBI 48% non-TBI 52% | Immunomagnetic purging 36% | BM 88% PB 12% | 43mo | 66% @ 43 mo | 83% @ 43 mo | No prognostic factors identified. | |